Intellia Therapeutics/ US45826J1051 /
| 7/7/2022 6:43:43 PM | Chg. +3.29 | Volume | Bid6:44:47 PM | Ask6:44:47 PM | High | Low |
|---|---|---|---|---|---|---|
| 63.80USD | +5.44% | 28,263 Turnover: 1.77 mill. |
63.70Bid Size: 100 | 69.29Ask Size: 129 | 64.10 | 60.14 |
GlobeNewswire
3/9
Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-5001 for the Treatment of A...
GlobeNewswire
3/1
Intellia Therapeutics Announces First Patient Dosed in Phase 1/2a Clinical Trial of NTLA-5001 for th...
GlobeNewswire
2/28
Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an In...
GlobeNewswire
2/24
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Highlights R...
GlobeNewswire
2/23
Intellia Therapeutics Enters Lease Agreement to Build Manufacturing Facility for its CRISPR-based Th...
GlobeNewswire
2/15
Intellia and ONK Therapeutics Announce Collaboration to Advance Allogeneic CRISPR-Edited NK Cell The...
GlobeNewswire
1/5
Intellia Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, ...
GlobeNewswire
1/5
Intellia Therapeutics and Kyverna Therapeutics Announce Collaboration to Develop Next-Generation All...
GlobeNewswire
12/13/2021
Intellia Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the...
GlobeNewswire
12/9/2021
SparingVision Strengthens Leadership Team with the Appointment of Dr Mehdi Gasmi as Chief Operating ...
GlobeNewswire
11/22/2021
Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults wi...
GlobeNewswire
11/8/2021
Ring Therapeutics Strengthens Leadership Team with Three Executive Appointments
GlobeNewswire
11/5/2021
Intellia Therapeutics to Highlight Ex Vivo Genome Editing and CRISPR/Cas9 Manufacturing Advances at ...
GlobeNewswire
11/4/2021
Intellia Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Recent Company P...
GlobeNewswire
10/28/2021
Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2021 Earnings and Company Upd...
GlobeNewswire
10/21/2021
Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational C...
GlobeNewswire
10/20/2021
Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its Broad Genome Editi...
GlobeNewswire
10/13/2021
Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular The...
GlobeNewswire
10/13/2021
Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular The...
GlobeNewswire
10/12/2021
Intellia Therapeutics to Present New Preclinical Data Highlighting In Vivo and Ex Vivo Genome Editin...
GlobeNewswire
10/6/2021
Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-2002 for t...
GlobeNewswire
9/27/2021
Intellia Therapeutics to Present at Chardan’s 5th Annual Genetic Medicines Conference